Increasing Awareness and Safety Drives the Intravenous Immunoglobulin (IVIG) Market, According to New Report by Global Industry Analysts, Inc.

GIA announces the release of a comprehensive global report on Intravenous Immunoglobulin (IVIG) markets. The global market for Intravenous Immunoglobulin is projected to exceed US$9.0 billion by 2018, driven by increasing acceptance among consumers, whose confidence regarding the safety of these products is on the upswing. Factors such as rise in bleeding disorders, ballooning global population, and an increase in global per capita GDP are spurring growth of the Immunoglobulin market. Other stimulants to the global Intravenous Immunoglobulin market include greater awareness regarding medical benefits, off-label use, and increased identification of patients afflicted with primary immune deficiency.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend
Intravenous Immunoglobulin (IVIG): A Global Strategic Business Report

San Jose, California (PRWEB) August 22, 2012

Follow us on LinkedIn – Immunoglobulin provide life saving therapies for a range of generally rare and serious conditions, and are used in the treatment of specific conditions such as immune deficiencies and bleeding disorders, serving to replace missing blood elements and permitting afflicted individuals to survive and lead normal lives. In developing regions, IVIG is chiefly prescribed for acute conditions, and patients with chronic conditions are required to pursue other treatment options. Worldwide, over 10 million individuals suffer from Primary Immune Deficiency Disorder (PIDD).

IVIG usage is highest in the US, followed by Sweden, Austria, and France. Testing of IVIG as therapy in Alzheimer’s disease is underway, and approval for this treatment is expected to create a surge in demand for IVIG. Organizationally, the Intravenous Immunoglobulin market continues to witness structural reformations such as industry mergers, vertical integrations, and increased manufacturing competencies in a bid for stable growth and market proliferation. However, the supply of plasma lags behind demand for plasma products, and China which is experiencing considerable growth as a nation is a key contributor to the worldwide discrepancy between the supply and demand of plasma and its products.

The recession had minimal impact on the 2010 sales of plasma products and the IVIG market as these products are life saving, critical therapies that serve patient populations for which limited or no alternatives exist. Associations such as the National Hemophilia Foundation, Plasma Protein Therapeutics Association, and the Immune Deficiency Foundation successfully campaigned on behalf of fractionators and patients for the exclusion of plasma derived therapeutics from certain private health insurance and government provisions that are intended to reduce drug prices by allocating a greater portion of the burden to patients. Intravenous Immunoglobulin (IVIG) finds application in the treatment and/or management of a number condition for which no alternative exist. The applications cover a wide range of conditions related to Neurology, Hematology, Immunology, Dermatology, Nephrology, Rheumatology, and Ophthalmology among others.

Intravenous Immunoglobulin (IVIG) therapy is gaining acceptance among patients and healthcare providers for many disorders for which there are no alternative therapies. Immunoglobulins are separated and purified from human plasma. Immunoglobulins cannot be synthesized, and have no synthetic substitute. Obtaining high-quality plasma is an expensive and challenging exercise, and is dependent on the availability of human donors. The standard method for production of plasma-derived immunoglobulins, albumin, or blood clotting factors involves fractionation of the starting plasma. Fractionation is a highly complex procedure that is exclusive to plasma-derived therapeutics. The method utilizes a sequence of steps with differing standards of pH, temperature, and ethanol concentration to separate the various proteins. The costs of production for plasma-derived therapies such as immunoglobulin are around 70-75% of the sale price in comparison to about 20-25% for conventional chemical based therapeutics. Additionally the target population for the therapy is smaller, posing a challenge for companies involved in production of IVIG.

In the US alone, approximately 1 in 1200 individuals is diagnosed with Primary Immunodeficiency Disease (PID). Thousands more go undetected. Identification of most children with primary immunodeficiencies relies on the awareness of families and their physicians, followed by referrals to specialists trained in the management of these complex diseases. However, various patient support groups such as the National Primary Immunodeficiency Resource Center in the United States, and the Primary Immunodeficiency Association in the United Kingdom, as well as specialists, are currently promoting the use of 10 warning signs of primary immunodeficiency to help with the diagnosis of PID. As such, awareness and diagnosis of PID is increasing, especially in developed countries. Subsequently, demand for IVIg therapy is also increasing. Globally, the plasma based therapy industry is a highly regulated sector. Though legal implications and regulatory apparatus differ regionally, the key objective of the regulations is to safeguard recipients and provide competent therapies. The following broad criteria form the basis of the regulatory framework in the plasma therapy sector.

As stated by the new market research report on Intravenous Immunoglobulin (IVIG), the United States represents the largest market for Intravenous Immunoglobulin (IVIG). On the other hand, Asia-Pacific region represents the fastest growing market for Intravenous Immunoglobulin (IVIG).

Major players in the global marketplace include Baxter International Inc., Beijing Tiantan Biological Products Co. Ltd., Bharat Serums and Vaccines Ltd., Biotest AG, China Biologic Products Inc., CSL Limited, Grifols S.A, Guizhou Taibang Biological Products Co. Ltd., Huanlan Biological Engineering Inc., Kedrion S.p.A., LFB Group, Octapharma AG, OMRIX Biopharmaceuticals Ltd., Shanghai RAAS Blood Products Co. Ltd., and Sichuan Yuanda Shuyang Pharmaceutical Co. Ltd.

The research report titled “Intravenous Immunoglobulin (IVIG): A Global Strategic Business Report” announced by Global Industry Analysts, Inc., provides a comprehensive review of market trends, issues, drivers, company profiles, and other strategic industry activities. The report provides market estimates and projections by value (in US$ Million) for major geographic markets including the US, Canada, Europe, Asia-Pacific, and Rest of World.

For more details about this comprehensive market research report, please visit –
http://www.strategyr.com/Intravenous_immunoglobulin_IVIG_Market_Report.asp

About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) is a leading publisher of off-the-shelf market research. Founded in 1987, the company currently employs over 800 people worldwide. Annually, GIA publishes more than 1300 full-scale research reports and analyzes 40,000+ market and technology trends while monitoring more than 126,000 Companies worldwide. Serving over 9500 clients in 27 countries, GIA is recognized today, as one of the world's largest and reputed market research firms.

Follow us on LinkedIn

Global Industry Analysts, Inc.
Telephone: 408-528-9966
Fax: 408-528-9977
Email: press(at)StrategyR(dot)com
Web Site: http://www.StrategyR.com/

###


Contact

Attachments